Sugi Predict

Sugi Predict / Targets / KLK5

KLK5

Kallikrein-5 · Q9Y337 · KLK5 on Sugi Atlas →

38,734 patent compounds predicted against KLK5, 19,580 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL912875 SCHEMBL912875 0.85 11/20
SCHEMBL914380 SCHEMBL914380 0.69 11/20
SCHEMBL914283 SCHEMBL914283 0.73 10/20
SCHEMBL915741 SCHEMBL915741 0.59 9/20
SCHEMBL912869 SCHEMBL912869 0.57 9/20
SCHEMBL914390 SCHEMBL914390 0.43 9/20
SCHEMBL913416 SCHEMBL913416 1.00 8/20
SCHEMBL914043 SCHEMBL914043 0.61 8/20
SCHEMBL913630 SCHEMBL913630 0.60 8/20
SCHEMBL914160 SCHEMBL914160 0.60 8/20
SCHEMBL914308 SCHEMBL914308 0.58 8/20
SCHEMBL914010 SCHEMBL914010 0.57 8/20
SCHEMBL914131 SCHEMBL914131 0.54 8/20
SCHEMBL914127 SCHEMBL914127 0.51 8/20
SCHEMBL595360 SCHEMBL595360 0.68 7/20
SCHEMBL948900 SCHEMBL948900 0.51 7/20
SCHEMBL247530 SCHEMBL247530 0.50 7/20
SCHEMBL915062 SCHEMBL915062 0.61 6/20
SCHEMBL914093 SCHEMBL914093 0.59 6/20
SCHEMBL913679 SCHEMBL913679 0.51 6/20

Clinical trials — most relevant to KLK5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein PHASE4UNKNOWN
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism PHASE4COMPLETED
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. PHASE3RECRUITING
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer PHASE2COMPLETED
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer PHASE2COMPLETED
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA PHASE1/PHASE2RECRUITING
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy PHASE2RECRUITING
Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer PHASE2COMPLETED
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy PHASE2COMPLETED
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer PHASE2COMPLETED
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery PHASE1/PHASE2COMPLETED
Prostate Cancer Vaccines PHASE1/PHASE2RECRUITING
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide PHASE2UNKNOWN
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME PHASE1COMPLETED
Study to Assess PK, Safety and Tolerability in Healthy Subjects PHASE1COMPLETED
A Phase I Clinical Study of a Single Dose of KLA480 PHASE1RECRUITING
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21 PHASE1COMPLETED
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. PHASE1COMPLETED
A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer PHASE1COMPLETED
Urinary Kallikrein and Hypertension: A Prospective Study nanCOMPLETED
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population nanRECRUITING
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland nanUNKNOWN
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion nanRECRUITING
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. nanCOMPLETED
The Contact Activation System and Ulcerative Colitis nanCOMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer nanCOMPLETED
Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease nanCOMPLETED
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KLK5 binder may also engage these)

ProteinNameSimilarity
KLK3 Prostate-specific antigen 0.982 landscape →
KLK2 Kallikrein-2 0.981 landscape →
KLK13 Kallikrein-13 0.981 landscape →
KLK7 Kallikrein-7 0.980 landscape →
P33619 — 0.979 P33619 →
P56435 — 0.978 P56435 →
P21842 — 0.977 P21842 →
P09650 — 0.977 P09650 →
A7WPL7 — 0.977 A7WPL7 →
Q9QYN3 — 0.976 Q9QYN3 →
Q9H2R5 — 0.975 Q9H2R5 →
P79204 — 0.975 P79204 →
O46683 — 0.975 O46683 →
P50341 — 0.975 P50341 →
O43240 — 0.975 O43240 →
Q07276 — 0.974 Q07276 →
CMA1 Chymase 0.974 landscape →
Q6DT45 — 0.973 Q6DT45 →
PRTN3 Myeloblastin 0.973 landscape →
P50342 — 0.972 P50342 →
P50339 — 0.972 P50339 →
KLK6 Kallikrein-6 0.972 landscape →
P80219 — 0.971 P80219 →
P52195 — 0.971 P52195 →
Q03238 — 0.971 Q03238 →
Q61096 — 0.971 Q61096 →
P21844 — 0.971 P21844 →
Q28773 — 0.971 Q28773 →
Q61955 — 0.971 Q61955 →
Q7JIG6 — 0.970 Q7JIG6 →